雷利度胺联合利妥昔单抗治疗复发性滤泡性淋巴瘤的疗效

发布时间：2018-06-20 06:13

本文选题：雷利度胺 + 利妥昔单抗　；参考：《广东医学》2017年21期

【摘要】：目的评估雷利度胺联合利妥昔单抗治疗滤泡性淋巴瘤的有效性和安全性。方法回顾性分析23例复发性滤泡性淋巴瘤患者并随访至2016年4月。根据是否联合使用利妥昔单抗分为两组。单纯治疗组:雷利度胺15 mg/d,第1~21天,然后停药7 d;第2个周期剂量加到20 mg,一共12个周期。联合治疗组:雷利度胺治疗基础上+利妥昔单抗每周375 mg/m2,持续4周。评估两组的不良反应及生存期,并运用统计学软件进行对比分析。结果单纯治疗组10例,联合治疗组13例。单纯治疗组有8例(80%),联合治疗组有10例(76.9%)患者完成了12个周期的治疗。两组临床缓解率比较差异无统计学意义(70%vs.84.6%,P=0.401)。不良反应中性粒细胞减少症(80%vs.76.9%,P=0.704)、疲劳(40%vs.46.2%,P=0.768)两组间差异无统计学意义,血栓形成(60%和15.4%,P=0.026)两组差异有统计学意义。平均随访3年发现,单纯治疗组的平均进展时间为(2.1±0.15)年,联合治疗组为(3.5±0.21)年两组差异有统计学意义(P0.001)。单纯治疗组生存期为(3.2±0.46)年,联合治疗组生存期为(4.7±0.32)年,两组差异无统计学意义(P=0.36)。结论雷利度胺联合利妥昔单抗治疗复发性滤泡性淋巴瘤患者是安全有效的,较单独使用雷利度胺更能延长患者生存期,控制疾病进展。
[Abstract]:Objective to evaluate the efficacy and safety of rilidomide combined with rituximab in the treatment of follicular lymphoma. Methods 23 patients with recurrent follicular lymphoma were retrospectively analyzed and followed up until April 2016. They were divided into two groups according to whether they were used in combination with rituximab. Treatment group: redox 15 mg / d, day 1: 21, and then stopped for 7 days; the second cycle dose was added to 20 mg for a total of 12 cycles. Combined treatment group: rituximab 375 mg / m ~ 2 per week for 4 weeks based on rituximab treatment. The adverse reactions and survival time of the two groups were evaluated and compared with statistical software. Results there were 10 cases in the treatment group and 13 cases in the combined treatment group. There were 8 cases in the treatment group and 10 cases in the combined treatment group. There was no significant difference in the clinical remission rate between the two groups. There was no significant difference between the two groups in adverse reaction neutropenia (vs.76.9P 0.704) and fatigue (40vs.46.2). There was no significant difference between the two groups. There was a significant difference between the two groups in thrombus formation (60%) and 15.4% (P 0.026). The average follow-up time was 2.1 卤0.15 years in the simple treatment group and 3.5 卤0.21 years in the combined treatment group. There was significant difference between the two groups (P 0.001). The survival time was 3.2 卤0.46 years in the simple treatment group and 4.7 卤0.32 years in the combined treatment group. There was no significant difference between the two groups. Conclusion Rilidomide combined with rituximab is safe and effective in the treatment of recurrent follicular lymphoma.
【作者单位】：河南科技大学临床医学院、河南科技大学第一附属医院药剂科;河南科技大学临床医学院、河南科技大学第一附属医院神经内科;河南科技大学临床医学院、河南科技大学第一附属医院血液科;
【基金】：河南省医学科技攻关计划项目(编号:201504016)
【分类号】：R733

【相似文献】